1. Jokinen, E. (2014). Obesity and cardiovascular disease. Minerva Pediatrica, 67(1), 25–32.
2. Foley, R. N., Parfrey, P. S., & Sarnak, M. J. (1998). Epidemiology of cardiovascular disease in chronic renal disease. Journal of the American Society of Nephrology: JASN, 9(12 Suppl), S16-23.
3. Carter, A. M. (2012). Complement activation: An emerging player in the pathogenesis of cardiovascular disease. Scientifica. https://doi.org/10.6064/2012/402783
4. Farsad, B. F., Alavi, S. M., Ghorbanian, G., Fahimi, F., Ghaemmaghami, Z., Mehr, A. Z., & Bakhshandeh, H. (2019). The therapeutic efficnecy of ranolazine in comparison with conventional therapy in diabetic individuals with ischemic heart disease; a randomized clinical trial. Journal of Renal Injury Prevention, 9(1), e04–e04.
5. Rahimi, N. (2017). Defenders and challengers of endothelial barrier function. Frontiers in Immunology, 8, 1847.